About the Company
Halozyme Therapeutics is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $HALO News
Mahesh Krishnan Elected to Halozyme's Board of Directors
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of ...
Halozyme to Report First Quarter 2024 Financial and Operating Results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and ...
9 Analysts Have This To Say About Halozyme Therapeutics
Analysts have recently evaluated Halozyme Therapeutics and provided 12-month price targets. The average target is $53.78, ...
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
If you have a high tolerance for volatility then the biotech sector might be for you. Biotech stocks can range from ...
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
Halozyme Therapeutics (HALO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...
Halozyme Therapeutics gets grant for injection device with safety features for medicament administration
Discover the innovative injection device patented by Halozyme Therapeutics Inc, ensuring safe and effective medication delivery to patients. Explore the unique features and components designed for ...
Buy Rating Affirmed for Halozyme on OCREVUS SC Prospects and Enhanze Technology Potential
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...
Breast Cancer Therapeutics Market Sizing the Unseen Unveiling the Future of Market Opportunities
Growing acceptance of therapeutic drugs due to factors such as the blocking of estrogen from binding to tumor cells, the risk of distant reappearance, the lowering of the risk of reappearance in the ...
News - Drug delivery
The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, ...
Loading the latest forecasts...